Price
$21.65-61.78%Social Signal Score
Analyst Ratings
17 analysts52-week range
- Last close
- $21.65
- Off 52w high
- -47.9%
- 200-day average
- $26.84
- vs 200-day
- -19.4%
Revenue
$98.29M+8128.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Larry L. Wood
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 888
- Beta
- 0.84
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.00
Financials
Revenue
$98.29M+8128.6%Net Income
$-26.52MEBITDA
$-23.18MFree Cash Flow
$-9.65MEPS (diluted)
$-0.46Shares Outstanding (diluted)
57.33M+1932.7%Operating Expenses
$92.52MCash & Debt
$218.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $308.05M | $-95.57M | $-1.72 |
| 2024 | $224.50M | $-91.41M | $-1.75 |
| 2023 | $136.19M | $-105.90M | $-2.24 |
| 2022 | $75.01M | $-87.15M | $-1.96 |
| 2021 | $34.47M | $-59.85M | $-1.37 |
| 2020 | $7.72M | $-53.02M | $-1.51 |
| 2019 | $6.17M | $-41.98M | $-1.25 |
Valuation
PRCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-16.67%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·4d ago·Neutral
…er 38th Annual Healthcare Conference on December 2, 2026 SAN JOSE, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 3:30 p.m. ET / 12:30 P…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
PROCEPT BioRobotics Q3 Earnings Call Highlights PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·30d ago·Neutral
PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
…ird Quarter 2026 Financial Results on November 4th, 2026 SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30…
View source ↗ - Newsprnewswire.com·69d ago·Negative
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 14, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsprnewswire.com·72d ago·Negative
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- The Law Offices of Frank R.
View source ↗ - Newsnewsfilecorp.com·88d ago·Positive
Notice to Long-Term Shareholders of PROCEPT BioRobotics Corporation (PRCT): Grabar Law Office Investigates Claims on Your Behalf Philadelphia, Pennsylvania--(Newsfile Corp. - August 26, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT). What is This Investigation About?
View source ↗ - Newsfool.com·96d ago·Positive
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors? The purchase involved 23,900 shares at $20.85 per share, representing an investment of ~$498,000. The transaction expanded the CEO's total equity holdings by 8%.
View source ↗ - Newsprnewswire.com·97d ago·Negative
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Bensalem, Pa., Aug. 17, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsgurufocus.com·97d ago·Neutral
PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT PR N
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.24 per share
Typical surprise -1.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.46 vs $-0.39miss
- Tue, Aug 4$-0.47 vs $-0.46miss
- Wed, Apr 29$-0.56 vs $-0.55miss
- Wed, Feb 25$-0.53 vs $-0.32miss
- Tue, Nov 4$-0.38 vs $-0.41beat
- Wed, Aug 6$-0.35 vs $-0.41beat
Estimates and results for PRCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRCT officers and directors.
- Bought
- $11.8m
- Sold
- $5.4m
9 trades
23 trades
- Sharma Poojasold
- Nouri Alalehsold
- Templin Barry Lsold
- Waters Kevinsold
- Wood Larry Lbought
- Nouri Alalehsold
- Waters Kevinsold
- Templin Barry Lsold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
